“The development of the novel drug, TE-1146, the CD38 specific antibody drug conjugate (ADC)” was selected as a significant case
We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, an affiliate company of T-E PHARMA, will
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection
On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning
We’re proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, will be presenting at the 4th World
Website link: https://news.gbimonthly.com/tw/article/show.php?num=75729&page=1
Great News! Immunwork’s Latest Publication Offers a Promising Clinical Solution for Diabetes, Obesity, and NASH Disease! The study, titled “2FA-Platform
Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th
We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to
Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been
